Objectives: The objective of this study was to analyse antimicrobial susceptibility testing data generated by the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) global surveillance programme for pathogens causing skin and soft tissue infections (SSTIs) in European countries in 2012.
Introduction
The IDSA broadly classifies skin and soft tissue infections (SSTIs) as purulent (furuncle, carbuncle and abscess) and non-purulent (necrotizing infection, cellulitis and erysipelas), categorizing the infection as mild, moderate and severe to guide optimal patient management. 1 Regardless of anatomic site or severity, the aetiology of SSTIs most frequently involves aerobic Gram-positive cocci, specifically Staphylococcus aureus and b-haemolytic streptococci. 1 -8 Aerobic Gram-negative bacilli and anaerobes are most commonly isolated from patients with compromised immune systems or decreased vascular perfusion who may present with complicated, chronic or necrotizing polymicrobial wound infections (e.g. diabetic foot infections). 2, 5 Increasingly, the emergence and spread of antimicrobial resistance determinants and virulent clones, particularly associated with MRSA, has been demonstrated to compromise patient outcomes. 1 The dogma that hospital-associated MRSA is frequently MDR and isolates of community-associated MRSA commonly harbour the cytotoxin Panton -Valentine leucocidin (PVL) is becoming outdated. 5 MRSA epidemiology can no longer be predicted in terms of causative strain (hospital associated versus community associated) because of shifting epidemiology and mounting antimicrobial resistance.
The latest cephalosporin addition to the anti-MRSA therapeutic portfolio is ceftaroline fosamil. Ceftaroline, the active metabolite of the prodrug ceftaroline fosamil, is a broad-spectrum cephalosporin that inhibits PBP2a of MRSA as well as other Gram-positive cocci and Enterobacteriaceae that do not harbour ESBLs, inducible AmpC b-lactamases or carbapenemases. Ceftaroline fosamil was approved by the US FDA in October 2010 and by the EMA in August 2012. Ceftaroline fosamil is indicated for the treatment of patients with complicated SSTI caused by susceptible isolates of S. aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca as well as community-acquired pneumonia. 9 The Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance programme was established to study contemporary clinical isolates from hospitalized patients commonly associated with SSTIs, lower respiratory tract infections, complicated intra-abdominal infections and complicated urinary tract infections in Europe, the USA, Latin America, Asia Pacific, the Middle East and Africa. This report summarizes SSTI data from the AWARE surveillance programme in Europe for 2012.
Materials and methods

Bacterial isolates tested
The European section of the 2012 AWARE surveillance programme included laboratories in 62 medical centres in 17 countries (number of centres) [Austria (3), Belgium (4), Czech Republic (3), Denmark (1), France (5), Germany (6), Greece (3), Hungary (2), Italy (5), the Netherlands (1), Portugal (4), Romania (3), Russia (5), Spain (6), Sweden (3), Turkey (5) and the UK (3)]. The AWARE surveillance programme requests each participating laboratory to annually collect predefined numbers of isolates of selected bacterial species from patients with specific infection types (one isolate per patient). The AWARE surveillance programme is not intended to evaluate the prevalence of organisms causing specific infections, but rather seeks to track the in vitro activities of ceftaroline and relevant comparator agents over time against organisms known to be frequent pathogens in specific infection types. In the case of SSTIs, the AWARE surveillance programme focuses on the principal pathogens S. aureus (70 -95 isolates per centre) and b-haemolytic streptococci (16 -21 isolates) as well as E. coli (25 -35 isolates), K. pneumoniae (15 -25 isolates), K. oxytoca (5 -7 isolates) and Proteus mirabilis (4-6 isolates). In 2012, the participating medical centre laboratories in Europe, Turkey and Russia collected 2583 S. aureus (1116 MSSA and 1467 MRSA), 462 b-haemolytic streptococci, 349 E. coli, 215 K. pneumoniae and 74 K. oxytoca from patients with SSTIs for the AWARE surveillance programme. All isolates were shipped to International Health Management Associates (Schaumburg, IL, USA), where their identities were confirmed using a Bruker Biotyper MALDI-TOF spectrometry instrument (Bruker Daltonics, Billerica, MA, USA).
Antimicrobial susceptibility testing
Antimicrobial susceptibility testing was performed at International Health Management Associates using in-house-prepared broth microdilution panels. All components of broth microdilution testing, including panel manufacture, storage, inoculation, incubation, interpretation and quality control, were conducted following current CLSI guidelines. 10, 11 Custom panel configurations were produced for staphylococci, streptococci and Enterobacteriaceae. MICs were interpreted using both CLSI and EUCAST MIC breakpoints when available.
11,12 CLSI has not published breakpoints for tigecycline; therefore, FDA MIC interpretative breakpoints [S. aureus, ≤0.5 mg/L (susceptible); Streptococcus spp. other than Streptococcus pneumoniae, ≤0.25 mg/L (susceptible); and Enterobacteriaceae, ≤2 mg/L (susceptible), 4 mg/L (intermediate) and ≥8 mg/L (resistant)] were used for this agent. 13 EUCAST does not publish breakpoints for ceftaroline for streptococci, but rather specifies that susceptibility to this b-lactam can be inferred from testing benzyl penicillin. 12 Isolates of S. aureus were assigned an MSSA or MRSA designation based on their oxacillin MIC; an oxacillin MIC of ≤2 mg/L was interpreted as MSSA and an MIC of ≥4 mg/L as MRSA. 11 All isolates of S. aureus with ceftaroline MICs of 2 or 4 mg/L were confirmed by repeated MIC testing and WGS was performed to enable sequence-based analyses and determine the resistance mechanisms associated with these isolates.
14 E. coli, K. pneumoniae and K. oxytoca were screened for an ESBL phenotype (ceftazidime or aztreonam MIC of .1 mg/L) and confirmed as ESBL producers using combination clavulanic acid-based testing, according to CLSI guidelines. 11 
Results
The 1116 isolates of MSSA tested were highly susceptible (.99% susceptible) to ceftaroline, vancomycin, daptomycin, linezolid and tigecycline ( Table 2 ). The two ceftaroline-resistant isolates identified in this study (MIC, 4 mg/L) exceeded the ceftaroline-susceptible breakpoint (≤1 mg/L) by two doubling dilutions. Both isolates were determined to be ST228. The following PBP2a substitutions were observed: Glu239Lys (one isolate) and Asn146Lys, Ile563Thr (one isolate). Table 3 depicts the association between the ceftaroline MIC and MICs of the other antimicrobial agents tested against isolates of MRSA. We observed that as the ceftaroline MIC increased from ≤0.25 to ≥2 mg/L, the percentage susceptibility of isolates to minocycline, clindamycin, erythromycin, levofloxacin and moxifloxacin decreased in a stepwise manner by 30% -50%. Tigecycline demonstrated a notable 8.8% decrease in percentage susceptibility as ceftaroline MICs increased from ≤0.25 to ≥2 mg/L.
MSSA and MRSA were isolated from different SSTI specimen sources in approximately equivalent proportions. In summary, wounds accounted for 42.8% (n ¼ 628) of specimens growing MRSA and 56.3% (n¼809) of specimens growing MSSA, respectively. Similarly, abscesses accounted for 16.0% (n¼188) of MRSA and 16.8% (n ¼ 235) of MSSA; skin ulcers for 6.7% (n ¼ 99) of MRSA and 14.4% (n¼161) of MSSA; and other specimen types for 17.8% (n¼262) of MRSA and 18.0% (n¼201) of MSSA, respectively. Karlowsky et al. 
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All isolates of b-haemolytic streptococci were susceptible to ceftaroline, penicillin, vancomycin, daptomycin, linezolid and tigecycline (Table 1) ; ceftaroline was the most potent of these five agents (i.e. lowest MICs). On a gram-per-gram basis, ceftaroline was at least as potent as penicillin against b-haemolytic streptococci.
Ceftaroline inhibited 87.5% of ESBL-negative E. coli, 92.3% of ESBL-negative K. pneumoniae, 93.2% of ESBL-negative K. oxytoca and 85.1% of ESBL-negative P. mirabilis (Table 4) . Ceftaroline was more potent against ESBL-negative isolates of E. coli, K. pneumoniae, K. oxytoca and P. mirabilis when compared with ESBL-positive isolates. Among ESBL-positive E. coli and ESBL-positive K. pneumoniae, 31.8% and 60.0% of isolates and 18.0% and 23.4% of isolates, respectively, were susceptible to cefepime and piperacillin/tazobactam.
Discussion
Greater than 99% of MSSA isolates and all isolates of b-haemolytic streptococci tested in the current study ( Karlowsky et al. 15, 16 These data suggest, in combination with data generated by the current study, that there is not a trend towards decreasing susceptibility to ceftaroline among MRSA causing SSTIs in the European region. Our data indicate that isolates of MRSA that are non-susceptible to ceftaroline are geographically dependent and perhaps clonal as 81.6% (93/ 114) of ceftaroline-intermediate and -resistant isolates were from laboratories in only four countries (Russia, Turkey, Italy and Hungary) ( Table 2 ). In contrast, only 1% of MRSA isolated in the USA from 2009 to 2012 were ceftaroline intermediate with no resistant isolates reported to date. 17, 18 Available data indicate that ceftaroline-resistant isolates of S. aureus remain very rare worldwide (Table 1) . 15 -19 Ceftarolineintermediate isolates (MIC, 2 mg/L) are infrequently observed; however, pharmacokinetic/pharmacodynamic target attainment studies using Monte Carlo simulations predict that 600 mg of ceftaroline every 12 h provides the %T .MIC target attainment for key skin pathogens, including S. aureus, with ceftaroline MICs of ≤2 mg/L in .95% of instances. 20 A 2008 European surveillance study of SSTI isolates detected four isolates of MRSA, all from the same medical centre in Greece, with ceftaroline MICs of 4 mg/L. 16 These isolates were shown to be clonal by spa typing and MLST (Hungarian/Brazilian clone, spa t037, ST239), to have mecA mutations at N146K, N204K, E150K and H351N, to be PVL negative and to harbour SCCmec type IIIA. Subsequently, Alm et al.
14 studied four additional MRSA isolates with ceftaroline MICs of 8 mg/L recovered from patients in Thailand and Spain as a part of the AWARE 2010 global surveillance programme. These isolates were also determined to be epidemiologically related (ST228-I) and to have PBP2a mutations at Glu239Lys (identified as a non-penicillin-binding or dimerization domain) and at Glu447Lys (identified as a penicillin-binding or transpeptidase domain). Alm et al.
14 then developed a model of PBP2a-mediated ceftaroline resistance in S. aureus based on structural analysis of PBP2a in ceftaroline-resistant variants. In 2014, Long et al. 21 published the first report of an isolate of MRSA with high-level resistance to ceftaroline (MIC, .32 mg/L). The isolate in their report was cultured from blood and sputum of a cystic fibrosis patient in the USA following therapy with ceftaroline. The isolate demonstrated a small colony variant phenotype, was ST5, a common US clonal type, and had a combination of two contiguous amino acid changes in PBP2a, specifically Y446N and E447K. The authors subsequently constructed isogenic mutant strains and performed inhibition studies to confirm the molecular basis of ceftaroline resistance in their patient strain. 21 Mushtaq et al. 22 have demonstrated it is highly unlikely that ceftaroline will select spontaneous resistant mutants of MSSA or MRSA on serial exposure. Population analysis profiling has demonstrated that certain isolates of S. aureus harbour unstable ceftaroline-heteroresistant subpopulations with a frequency of 1 in 10 4 to 10 5 organisms; the mechanism of heteroresistance development is unknown. 23 However, to date, there have been no reports of clinical failures due to ceftaroline heteroresistance and in vitro data suggest that ceftaroline retains its activity against such heteroresistant isolates of MRSA. 24 Strengths of the current dataset are that the isolates tested are from a wide variety of countries in the European region, that their identities were confirmed by MALDI-TOF before antimicrobial susceptibility testing and that all isolates were tested in a single, central, accredited (College of American Pathologists) laboratory adhering to CLSI guidelines and employing strict quality control. Unusual MIC results were repeated to confirm phenotypes. Two nonsusceptible MSSA, one each from Italy and Germany, were rare isolates that tested at the high end of the oxacillin or cefoxitin susceptible breakpoint and perhaps represented a heteroresistant culture. Ideally, these MSSA isolates should have been probed for the mecA gene for absolute verification. Another weakness of the study was that the data generated for laboratories within a country cannot be extrapolated to represent all isolates or geographic areas within that country. Therefore, there is a chance that the testing may over-or under-represent the rates of ceftaroline-intermediate and -resistant isolates, or other susceptibility trends, reported. As a non-prevalence-based study, no inference can be made as to species prevalence from SSTIs. The sampling pattern was used mainly to provide a robust collection of targeted pathogens for ceftaroline therapy.
In conclusion, we found that ceftaroline demonstrated potent in vitro activity against MSSA (MIC 90 , 0.25 mg/L), MRSA (MIC 90 , 1 mg/L), b-haemolytic streptococci (MIC 90 , 0.008 -0.015 mg/L) and ESBL-negative E. coli, K. pneumoniae and K. oxytoca (MIC 90 , 0.5-1 mg/L) isolated in 62 medical centre laboratories in 17 countries in the European region in 2012. Isolates of S. aureus resistant to ceftaroline are very rare (0.08%) while ceftaroline-intermediate isolates are largely restricted to specific geographic regions (81.0% of ceftaroline-intermediate isolates were from Russia, Turkey, Italy and Hungary). We observed an association between increases in ceftaroline MICs from ≤0.25 to ≥2 mg/L and decreases in MRSA susceptibility to tigecycline, minocycline, clindamycin, erythromycin, levofloxacin and moxifloxacin. Given the importance of anti-MRSA agents to the treatment of a multitude of infections, continued surveillance through programmes such as AWARE is mandatory to understanding current and possible future trends in antimicrobial resistance.
